cyclohexanol has been researched along with raloxifene hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mueck, AO; Seeger, H | 1 |
| Kumar, P; Song, ZH | 1 |
1 review(s) available for cyclohexanol and raloxifene hydrochloride
| Article | Year |
|---|---|
Hormone therapy after endometrial cancer.
Topics: Age Distribution; Aged; Chemotherapy, Adjuvant; Cyclohexanols; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometrial Neoplasms; Estrogens; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Incidence; Middle Aged; Neoplasm Staging; Norpregnenes; Progestins; Raloxifene Hydrochloride; Risk Assessment; Survival Analysis; Treatment Outcome; Venlafaxine Hydrochloride | 2003 |
1 other study(ies) available for cyclohexanol and raloxifene hydrochloride
| Article | Year |
|---|---|
Identification of raloxifene as a novel CB2 inverse agonist.
Topics: Benzoxazines; Binding, Competitive; Bone Density Conservation Agents; Colforsin; Cyclic AMP; Cyclohexanols; Dose-Response Relationship, Drug; Dronabinol; Drug Approval; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Morpholines; Naphthalenes; Raloxifene Hydrochloride; Receptor, Cannabinoid, CB2; Transfection; Tritium; United States; United States Food and Drug Administration | 2013 |